製品番号: HY-N0864

Macranthoidin B

(別名: Macranthoiside I)

カスタマーレビュー

Based on 1 Customer Validation

Macranthoidin B (Macranthoiside I) is an orally active triterpene saponin. Macranthoidin B inhibits epithelial-mesenchymal transition in endometriosis via the COX‑2/PGE2 pathway, and also induces tumor cell apoptosis and inhibits their proliferation by regulating metabolism and increasing ROS levels. Macranthoidin B can be used in studies related to endometriosis, colorectal cancer and hepatocellular carcinoma.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 98.35%
CAS 番号: 136849-88-2
分子式: C₆₅H₁₀₆O₃₂
分子量:1399.52

保管条件:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Macranthoidin B 構造式

CAS 番号: 136849-88-2

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

COX アイソフォーム固有の製品をすべて表示 :

Caspase アイソフォーム固有の製品をすべて表示 :

体外実験

Macranthoidin B (0-500 μM; 24 h) inhibits migration and invasion of primary endometriotic stromal cells and HEC1-B endometrial cancer cells, and suppresses epithelial-mesenchymal transition and the COX-2/PGE2 pathway^[1].
Macranthoidin B (20-400 μM; 24-48 h) reduces the viability of HCT-116 colorectal cancer cells in a dose-dependent manner, induces cell apoptosis, and promotes ROS generation^[2].
Macranthoidin B (20-400 μM; 48 h) dose-dependently promotes ROS production in HCT-116 colorectal cancer cells^[2].
Macranthoidin B (20-400 μM; 48 h) dose-dependently downregulates the mRNA expression of antioxidant enzymes MnSOD and GSH-Px in HCT-116 colorectal cancer cells^[2].
Macranthoidin B (100-400 μM; 24 h) inhibits the proliferation of Hepa1-6 cells in a dose-dependent manner and increases intracellular ROS levels^[3].
Macranthoidin B (100-400 μM; 24 h) dose-dependently induces oxidative stress in Hepa1-6 cells, which is characterized by a significant increase in MDA levels and significant decreases in GSH levels, SOD activity and GSH-Px activity at all tested concentrations^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

HCT-116 colorectal cancer cells
Concentration:

20, 50, 100, 200, 400 μM
Incubation Time:

48 h
Result:

Caused a dose-dependent decrease in cell viability, with significant reductions observed at all tested concentrations relative to control.

Western Blot Analysis^[2]

Cell Line:

HCT-116 colorectal cancer cells
Concentration:

20, 50, 100, 200, 400 μM
Incubation Time:

72 h
Result:

Altered caspase-3 expression, increasing levels of cleaved caspase-3 in a dose-dependent manner.

体内実験

Macranthoidin B (3-27 mg/kg; p.o.; daily; 28 days) inhibits the growth of ectopic lesions in a rat autotransplantation endometriosis model^[1].
Macranthoidin B (16 mg/kg; i.p.; once daily; for 3 consecutive weeks) significantly inhibits the growth of colorectal cancer xenografts in nude mice by inducing tumor cell apoptosis^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Sprague-Dawley (SD) (female, 6-7 weeks old, 180-220 g, autograft implantation of endometrial segments endometriosis model)^[1]
Dosage:

3 mg/kg; 9 mg/kg; 27 mg/kg
Administration:

p.o.; daily; 28 days
Result:

Reduced post-treatment ectopic endometrial volume compared to pretreatment.
Resulted in transplants with less adhesion and fewer surface blood vessels (9 and 27 mg/kg doses).
Improved pathological morphology of ectopic tissues, with fewer and smaller pseudo glands, reduced microvascularity, and decreased inflammatory cell infiltrations.
Decreased serum estradiol (E2) levels and increased serum progesterone (PROG) levels compared to the untreated endometriosis group.
Increased mRNA and protein expression of epithelial marker Cdh1/E-cadherin in ectopic tissues.
Decreased mRNA expression of mesenchymal markers Cdh2, Vim, Twist, Slug, Snail, Zeb1, and Zeb2, as well as protein expression of mesenchymal markers N-cadherin and Vimentin in ectopic tissues.
Reduced mRNA expression of Ptgs2 and Ptges, and decreased protein levels of COX-2 and PGE2 in ectopic tissues.

Animal Model:

Nude mice (4 weeks old; half male, half female; engrafted with human HCT-116 colorectal cancer cells)^[2]
Dosage:

16 mg/kg
Administration:

i.p.; once daily; 3 weeks
Result:

Reduced tumor volume significantly compared to vehicle control.
Reduced tumor weight significantly compared to vehicle control.
Increased TUNEL-positive cells per field significantly compared to vehicle control.
Elevated levels of cleaved caspase-3 compared to vehicle control.

化学情報

CAS 番号 136849-88-2
性状 Solid
分子量 1399.52
分子式 C₆₅H₁₀₆O₃₂
Color White to light brown
SMILES

O=C([C@]1(CCC(C)(C)C2)[C@]2([H])C3=CC[C@@]4([H])[C@@](C)(CC[C@]5([H])[C@@]4(CC[C@H](O[C@@](OC[C@H](O)[C@@H]6O)([H])[C@@H]6O[C@@](O[C@@H](C)[C@H](O)[C@H]7O[C@]([C@@H]([C@@H](O)[C@@H]8O[C@]([C@@H]([C@@H](O)[C@@H]9O)O)([H])O[C@@H]9CO)O)([H])O[C@@H]8CO)([H])[C@@H]7O)[C@@]5(C)CO)C)[C@]3(C)CC1)O[C@@H]([C@@H]([C@@H](O)[C@@H]%10O)O)O[C@@H]%10CO[C@@H]([C@@H]([C@@H](O)[C@@H]%11O)O)O[C@@H]%11CO
別名

Macranthoiside I
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
- Plants
- other families
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶剤 & 溶解度

体外:

H₂O : 100 mg/mL (71.45 mM; Need ultrasonic)

DMSO : 100 mg/mL (71.45 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

0.7145 mL

3.5727 mL

7.1453 mL

5 mM

0.1429 mL

0.7145 mL

1.4291 mL

10 mM

0.0715 mL

0.3573 mL

0.7145 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (1.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (1.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (1.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 100 mg/mL (71.45 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (286 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Ding Y, et al. Macranthoidin B restrains the epithelial-mesenchymal transition through COX-2/PGE₂ pathway in endometriosis. Front Pharmacol. 2024;15:1492098. Published 2024 Dec 12. [Content Brief]

[2]. Fan X, et al. Macranthoidin B Modulates Key Metabolic Pathways to Enhance ROS Generation and Induce Cytotoxicity and Apoptosis in Colorectal Cancer. Cell Physiol Biochem. 2018;46(4):1317-1330. [Content Brief]

[3]. Tan S, et al. Macranthoidin B (MB) Promotes Oxidative Stress-Induced Inhibiting of Hepa1-6 Cell Proliferation via Selenoprotein. Biol Trace Elem Res. 2023;201(1):368-376. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	0.7145 mL	3.5727 mL	7.1453 mL	17.8633 mL
	5 mM	0.1429 mL	0.7145 mL	1.4291 mL	3.5727 mL
	10 mM	0.0715 mL	0.3573 mL	0.7145 mL	1.7863 mL
	15 mM	0.0476 mL	0.2382 mL	0.4764 mL	1.1909 mL
	20 mM	0.0357 mL	0.1786 mL	0.3573 mL	0.8932 mL
	25 mM	0.0286 mL	0.1429 mL	0.2858 mL	0.7145 mL
	30 mM	0.0238 mL	0.1191 mL	0.2382 mL	0.5954 mL
	40 mM	0.0179 mL	0.0893 mL	0.1786 mL	0.4466 mL
	50 mM	0.0143 mL	0.0715 mL	0.1429 mL	0.3573 mL
	60 mM	0.0119 mL	0.0595 mL	0.1191 mL	0.2977 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Macranthoidin B

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Glycoside Compound Library

Oxygen Sensing Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Cell Death Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Lactylation Compound Library

COX アイソフォーム固有の製品をすべて表示

Caspase アイソフォーム固有の製品をすべて表示

生物活性

化学情報

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Macranthoidin B 関連分類

HY-N0864 関連分類